Medmix Sustainability Profile
Medmix AG, headquartered in Switzerland (CH), is a leading player in the precision dispensing and mixing solutions industry. Founded in 2021, the company emerged from a rich heritage of innovation, focusing on advanced technologies for the healthcare, consumer, and industrial sectors. With a strong presence in Europe, Asia, and the Americas, Medmix offers a diverse range of core products, including high-performance dispensing systems and mixing solutions that stand out for their reliability and efficiency. The company is recognised for its commitment to quality and sustainability, positioning itself as a trusted partner in various markets. Medmix has quickly established itself as a key competitor, leveraging its expertise to deliver tailored solutions that meet the evolving needs of its clients, thereby solidifying its reputation in the global marketplace.
DitchCarbon Score
How does Medmix's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medmix's score of 73 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medmix's reported carbon emissions
In 2024, Medmix reported total greenhouse gas emissions of approximately 73,000,000 kg CO2e, comprising 4,351,000 kg CO2e from Scope 1, 5,880,000 kg CO2e from Scope 2, and 63,355,000 kg CO2e from Scope 3 emissions. This reflects a slight decrease in Scope 1 emissions from 4,381,000 kg CO2e in 2023, while Scope 2 emissions increased from 1,214,000 kg CO2e in 2023. Scope 3 emissions also rose from 60,044,000 kg CO2e in 2023. Medmix has set ambitious climate commitments, aiming for a 50% reduction in absolute Scope 1 emissions by 2030 compared to 2019 levels. Additionally, they have committed to a long-term target of reducing absolute Scope 1, 2, and 3 emissions by 90% by 2050, also from a 2019 baseline. Near-term targets include an 80% reduction in Scope 1 and 2 emissions by 2029, and a 42% reduction in Scope 3 emissions within the same timeframe. Furthermore, Medmix has pledged to achieve net-zero greenhouse gas emissions across its value chain by 2050. These targets are aligned with the Science Based Targets initiative (SBTi) and are classified as consistent with the reductions required to limit global warming to 1.5°C. All emissions data and targets are sourced directly from Medmix AG, with no data cascaded from a parent or related organization.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 5,408,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,545,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 67,803,000 | 00,000,000 | 00,000,000 |
How Carbon Intensive is Medmix's Industry?
How Carbon Intensive is Medmix's Location?
Medmix's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Medmix has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Medmix's sustainability data and climate commitments